Assignee
PROPELLA THERAPEUTICS INC
US·8 granted patents·7 pending applications·17 citations·filing 2014–2024
Top patents by PatentIndex Score
15 records- 0195US11559534B2Abiraterone prodrugsPROPELLA THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·4 cites·23 claims
- 0295US10792292B2Abiraterone prodrugsPROPELLA THERAPEUTICS INC·Filed 2020·Granted Oct 6, 2020·10 cites·30 claims
- 0393US11957696B2Abiraterone prodrugsPROPELLA THERAPEUTICS INC·Filed 2022·Granted Apr 16, 2024·2 cites·21 claims
- 0481US10821088B2Pain relief compositions, manufacture and usesPROPELLA THERAPEUTICS INC·Filed 2014·Granted Nov 3, 2020·1 cites·31 claims
- 0580US2025099489A1Abiraterone prodrugsPROPELLA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0679US11737994B2Topical compositions for pain relief, manufacture and usePROPELLA THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·0 cites·22 claims
- 0778US12138273B2Abiraterone prodrugsPROPELLA THERAPEUTICS INC·Filed 2023·Granted Nov 12, 2024·0 cites·34 claims
- 0877US2024139212A1Abiraterone prodrugsPROPELLA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0972US11123315B2Topical compositions for pain relief, manufacture and usePROPELLA THERAPEUTICS INC·Filed 2020·Granted Sep 21, 2021·0 cites·1 claims
- 1071US2021100759A1Pain relief compositions, manufacture and usesPROPELLA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1164US2022249496A1Topical acyclovir formulations and uses thereofPROPELLA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1262US2025186463A1Abiraterone decanoate prodrugs and use in therapyPROPELLA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1361US11246872B2Topical acyclovir formulations and uses thereofPROPELLA THERAPEUTICS INC·Filed 2020·Granted Feb 15, 2022·0 cites·4 claims
- 1460US2025025417A1Oral abiraterone formulationsPROPELLA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1556US2024050447A1Abiraterone prodrugsPROPELLA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →